Log in

NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News

-0.71 (-8.12 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $8.03
50-Day Range
MA: $7.09
52-Week Range
Now: $8.03
Volume534,025 shs
Average Volume317,182 shs
Market Capitalization$394.59 million
P/E RatioN/A
Dividend YieldN/A
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Read More
Unity Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:UBX



Sales & Book Value

Annual SalesN/A



Market Cap$394.59 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have increased by 49.0% and is now trading at $8.03. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.03. View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

3 analysts have issued 12 month target prices for Unity Biotechnology's stock. Their forecasts range from $13.00 to $33.00. On average, they anticipate Unity Biotechnology's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 174.0% from the stock's current price. View analysts' price targets for Unity Biotechnology.

Has Unity Biotechnology been receiving favorable news coverage?

News articles about UBX stock have been trending neutral on Saturday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutUnity Biotechnology.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
  • Dr. Anirvan Ghosh, Director & CEO (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.95%), Geode Capital Management LLC (0.82%), Russell Investments Group Ltd. (0.45%), Nuveen Asset Management LLC (0.22%), Bank of New York Mellon Corp (0.16%) and Morgan Stanley (0.12%).

Which institutional investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Moloney Securities Asset Management LLC, State Street Corp, UBS Group AG, Squarepoint Ops LLC, Virtus ETF Advisers LLC, and JPMorgan Chase & Co..

Which institutional investors are buying Unity Biotechnology stock?

UBX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Geode Capital Management LLC, Investors Financial Group LLC, Verity Asset Management Inc., Nuveen Asset Management LLC, Alliancebernstein L.P., BNP Paribas Arbitrage SA, and Cit Bank NA Wealth Management.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $8.03.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $394.59 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.